Literature DB >> 25933960

Pharmacokinetics of cotinine in rats: a potential therapeutic agent for disorders of cognitive function.

Pei Li1, Wayne D Beck2, Patrick M Callahan3, Alvin V Terry3, Michael G Bartlett4.   

Abstract

BACKGROUND: Attention has been paid to cotinine (COT), one of the major metabolites of nicotine (NIC), for its pro-cognitive effects and potential therapeutic activities against Alzheimer's disease (AD) and other types of cognitive impairment. In order to facilitate pharmacological and toxicological studies on COT for its pro-cognitive activities, we conducted a pharmacokinetic (PK) study of COT in rats, providing important oral and intravenously (iv) PK information.
METHODS: In this study, plasma samples were obtained up to 48 h after COT was dosed to rats orally and iv at a dose of 3mg/kg. Plasma samples were prepared and analyzed using a sensitive liquid chromatography tandem mass spectrometry (LC-MS/MS) bioanalytical method, providing concentration profiles of COT and metabolites after oral and iv administrations.
RESULTS: The data were fitted into a one-compartment model and a two-compartment model for the oral and iv groups, respectively, providing important PK information for COT including PK profiles, half-life, clearance and bioavailability. The results suggested fast absorption, slow elimination and high bioavailability of COT in rats.
CONCLUSIONS: Several important facts about the PK properties in rats suggested COT could be a potential pro-cognitive agent. Information about the pharmacokinetics of COT in rats revealed in this study is of great importance for the future studies on COT or potential COT analogs as agents for improving cognition.
Copyright © 2014 Institute of Pharmacology, Polish Academy of Sciences. Published by Elsevier Urban & Partner Sp. z o.o. All rights reserved.

Entities:  

Keywords:  Cognition; Cotinine; Hydrophilic interaction chromatography; Pharmacokinetics; Tandem mass spectrometry

Mesh:

Substances:

Year:  2014        PMID: 25933960      PMCID: PMC4752176          DOI: 10.1016/j.pharep.2014.12.004

Source DB:  PubMed          Journal:  Pharmacol Rep        ISSN: 1734-1140            Impact factor:   3.024


  35 in total

1.  Effects of transdermal nicotine on cognitive performance in Down's syndrome.

Authors:  R Seidl; M Tiefenthaler; E Hauser; G Lubec
Journal:  Lancet       Date:  2000-10-21       Impact factor: 79.321

Review 2.  Pharmacotherapeutic approaches to the treatment of Alzheimer's disease.

Authors:  John B Standridge
Journal:  Clin Ther       Date:  2004-05       Impact factor: 3.393

3.  Application of Akaike's information criterion (AIC) in the evaluation of linear pharmacokinetic equations.

Authors:  K Yamaoka; T Nakagawa; T Uno
Journal:  J Pharmacokinet Biopharm       Date:  1978-04

4.  Pharmacokinetics of nicotine, cotinine, and 3'-hydroxycotinine in cigarette smokers.

Authors:  G Scherer; L Jarczyk; W D Heller; A Biber; G B Neurath; F Adlkofer
Journal:  Klin Wochenschr       Date:  1988

Review 5.  The amyloid hypothesis of Alzheimer's disease: progress and problems on the road to therapeutics.

Authors:  John Hardy; Dennis J Selkoe
Journal:  Science       Date:  2002-07-19       Impact factor: 47.728

Review 6.  Clinical pharmacokinetics of nicotine.

Authors:  C K Svensson
Journal:  Clin Pharmacokinet       Date:  1987-01       Impact factor: 6.447

7.  Nicotine and cotinine elimination pharmacokinetics in smokers and nonsmokers.

Authors:  N L Benowitz; P Jacob
Journal:  Clin Pharmacol Ther       Date:  1993-03       Impact factor: 6.875

8.  Cotinine selectively activates a subpopulation of alpha3/alpha6beta2 nicotinic receptors in monkey striatum.

Authors:  Kathryn O'Leary; Neeraja Parameswaran; J Michael McIntosh; Maryka Quik
Journal:  J Pharmacol Exp Ther       Date:  2008-02-27       Impact factor: 4.030

Review 9.  Desensitization of nicotinic acetylcholine receptors as a strategy for drug development.

Authors:  Jerry J Buccafusco; J Warren Beach; Alvin V Terry
Journal:  J Pharmacol Exp Ther       Date:  2008-11-20       Impact factor: 4.030

Review 10.  Estimating xenobiotic half-lives in humans from rat data: influence of log P.

Authors:  J G Sarver; D White; P Erhardt; K Bachmann
Journal:  Environ Health Perspect       Date:  1997-11       Impact factor: 9.031

View more
  4 in total

1.  Cotinine administration improves impaired cognition in the mouse model of Fragile X syndrome.

Authors:  Marta Pardo; Eleonore Beurel; Richard S Jope
Journal:  Eur J Neurosci       Date:  2016-11-12       Impact factor: 3.386

2.  Nicotine e-cigarette vapor inhalation and self-administration in a rodent model: Sex- and nicotine delivery-specific effects on metabolism and behavior.

Authors:  Valeria Lallai; Yen-Chu Chen; Mikayla M Roybal; Eashan R Kotha; James P Fowler; Andres Staben; Angelique Cortez; Christie D Fowler
Journal:  Addict Biol       Date:  2021-02-23       Impact factor: 4.280

3.  Molecular Insights Into Memory-Enhancing Metabolites of Nicotine in Brain: A Systematic Review.

Authors:  Alireza Majdi; Farzin Kamari; Saeed Sadigh-Eteghad; Albert Gjedde
Journal:  Front Neurosci       Date:  2019-01-15       Impact factor: 4.677

Review 4.  Cotinine: Pharmacologically Active Metabolite of Nicotine and Neural Mechanisms for Its Actions.

Authors:  Xiaoying Tan; Kent Vrana; Zheng-Ming Ding
Journal:  Front Behav Neurosci       Date:  2021-10-21       Impact factor: 3.617

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.